Biofrontera Inc. Form 8-K Summary
Business Context and Reporting Period
Biofrontera Inc. furnished a Form 8-K dated April 8, 2022, reporting the release of financial and operational results for the fourth quarter and fiscal year ended December 31, 2021. The filing identifies the company as a Delaware corporation headquartered in Woburn, Massachusetts, with common stock and warrants listed on Nasdaq under BFRI and BFRIW.
Financial Results and Other Metrics
The filing references the company’s financial and operational results but does not include the underlying press release text or specific financial figures. Accordingly, the filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other key financial metrics.
The press release reportedly contains non-GAAP financial measures and quantitative reconciliations to the most directly comparable GAAP measures.
Material Changes Versus Prior Period
The filing text does not provide sufficient detail to identify specific year-over-year or quarter-over-quarter changes.
Guidance, Outlook, Risks, and Unusual Items
No specific guidance, outlook, risk updates, contingencies, or unusual items are disclosed in the provided filing text. The results announcement was furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, except as otherwise expressly provided.
Investor Verification Items
- Obtain and review Exhibit 99.1, the April 8, 2022 press release, for the complete fourth-quarter and full-year 2021 results.
- Verify reported GAAP results and reconciliations for all non-GAAP measures.
- Review cash balances, operating cash flow, debt, liquidity, and any financing requirements disclosed in the press release.
- Assess management’s outlook, operating milestones, and material risks not included in the supplied filing text.